Companies Dominating the Prils Market
- Teva Pharmaceuticals Industries Ltd.
- Company Overview
- Business Strategy
- Key Product Offerings
- Financial Performance
- Key Performance Indicators
- Risk Analysis
- Recent Development
- Regional Presence
- SWOT Analysis
- Boehringer Ingelheim International GmbH
- Sun Pharmaceuticals Industries Ltd.
- Pfizer Inc.
- Mylan N.V
- F. Hoffmann-La Roche Ltd.
- Novartis AG
- Manus Aktteva Biopharma LLP
- Canagen Pharmaceuticals Inc.
- Lupin Limited
Browse key industry insights with market data tables & charts from the report:
Frequently Asked Questions (FAQ)
In the year 2025, the industry size of prils is evaluated at USD 2.51 billion.
The prils market size was valued at USD 2.27 billion in 2024 and is expected to reach USD 5.08 billion by 2037, expanding at around 6.4% CAGR during the forecast period i.e., between 2025-2037. Rising geriatric population and the growing incidences of cardiovascular diseases will boost the market growth.
Europe industry is predicted to account for largest revenue share of 31% by 2037, driven by increasing initiatives to assist the expansion of generic medications through pricing and reimbursement in the region.
The major players in the market are Teva Pharmaceuticals Industries Ltd., Boehringer Ingelheim International GmbH, Sun Pharmaceuticals Industries Ltd., Pfizer Inc., Mylan N.V, F. Hoffmann-La Roche Ltd., Novartis AG, Manus Aktteva Biopharma LLP, Canagen Pharmaceuticals Inc., Lupin Limited
